Business Wire

HCL-TECHNOLOGIES

21.2.2017 21:18:05 CET | Business Wire | Press release

Share
HCL Grant 2017 Winners Announced

Three winners of HCL Grant 2017 across categories of Environment, Health and Education were today announced at a ceremony held at HCL Technologies Hub, Noida. Shri Arun Jaitley, Hon’ble Union Minister of Finance and Corporate Affairs , presided over the ceremony as the Chief Guest and felicitated the winners. Each winning NGO receives a Grant of up to INR 5 crores.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170221006559/en/

At the occasion, Shri Arun Jaitley also released a compendium titled “The Fifth Estate - NGOs transforming Rural India in Environment, Health and Education , which is a compilation of all the finalists of the second edition of HCL Grant.

Shri Arun Jaitley, Hon’ble Union Minister of Finance and Corporate Affairs, congratulated the winners of HCL Grant 2017 and appreciated the work of HCL and the jury.

Addressing the gathering he said , “I must compliment HCL for going into the larger society, creating an independent jury, looking at areas which need support and getting the jury to select the best so that the winners can be role models for others.”

Malcolm Gladwell , an eminent author and speaker, attended the ceremony as a Special Guest and addressed the gathering comprising Board members, senior leadership and other distinguished guests from various walks of life.

The winning NGOs across three categories are:

  • Environment - Foundation of Ecological Security (Gujarat)
  • Health - Child in Need Institute (CINI) (West Bengal)
  • Education - MelJol (Maharashtra)

Ms. Robin Abrams, Chairperson of Jury, HCL Grant, said, “HCL Grant is so much more than the fund itself. The mark of the strategic value of any grant is leverage. From the focus on governance and sustainability, sharing of best practices and how corporates and their employees can engage with NGOs – HCL Grant delivers on strategic value for the NGOs of India and for India’s Fifth Estate. It is exciting to be a part of this kind of leverage.”

HCL Grant, a CSR commitment by HCL through HCL Foundation, envisions to contribute to rural development by strengthening NGOs through deep institutional involvement and commitment. The Grant stands testimony to the fact that only strong governance structures management capabilities and reliable impact measurement systems within NGOs can help them take up and sustain high impact, complex and social transformational projects.

The winning NGOs have been selected by an eminent jury panel. Members of the panel are Ms. Robin Abrams – Former President of Palm Computing, and the longest serving Board member of HCL Technologies; Dr. Isher Judge Ahluwalia - Leading Economist and Chairperson, Board of Governors, the Indian Council for Research on International Economic Relations; Ms. Pallavi Shroff - Eminent Legal Counsel, Shardul Amarchand Mangaldas & Co.; Mr. B.S. Baswan - Former Director, Indian Institute of Public Administration; Mr. Richard Lariviere - President, Field Museum, Chicago and Former President of the University of Oregon; Dr. John E. Kelly – Senior Vice President, Cognitive Solutions and Research, IBM Corporation; and Mr. Shiv Nadar – Founder & Chairman, HCL and Shiv Nadar Foundation.

For more information please visit www.hcltech.com/HCL-Grant .

Contact:

HCL Technologies
Ajay Davessar, +91 120 43828280
VP & Global Head - Corporate Communications
Ajay.davessar@hcl.com

Link:

ClickThru

Social Media:

https://www.facebook.com/https://www.facebook.com/HCLTechnologies

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye